Side effects may occur during treatment with KADCYLA, and these can be mild or serious. It’s important to know what side effects may happen and what to watch out for during your treatment with KADCYLA. Talk to your doctor about any and all side effects you experience, even if you think they are minor.
KADCYLA can cause severe liver problems that can be life-threatening. KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure). Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects.
Other possible serious side effects include:
The most common side effects in people taking KADCYLA for metastatic breast cancer are tiredness, nausea, pain that affects the bones, muscles, ligaments, and tendons, bleeding, low platelet count, headache, liver problems, constipation, and nosebleeds.
Talk to your doctor about any side effects you experience. Learn what to watch out for and get tips for certain side effects below.
KADCYLA has been studied in people with HER2+ metastatic breast cancer. These people had already received Herceptin and a taxane (chemotherapy). In this study, people took either KADCYLA or a combination of Tykerb® (lapatinib)* and Xeloda® (capecitabine).
In this study, less than 6% of people who took KADCYLA or lapatinib and capecitabine lost their hair (3.9% in the KADCYLA arm and 5.1% in the lapatinib and capecitabine arm).
*Tykerb is a registered trademark of GlaxoSmithKline.
Remember, the tips mentioned below may not work for everyone. Be sure to talk with your doctor before trying any of these tips.
This image shows a normal cell with a normal amount of HER2, in which cells grow and divide normally; and a HER2+ cancer cell with too much HER2, in which cells grow and divide faster.
This image shows lymph nodes to which breast cancer can spread, such as those around or near the collarbone, in the armpits, and near the breastbone.
Overview
This image shows what your treatment plan may look like.
Details
Overview
This image provides information about neoadjuvant and adjuvant treatment.
Details
Neoadjuvant treatment (before surgery)
One of the goals of neoadjuvant treatment is to help reduce or get rid of cancer cells before surgery.
Adjuvant treatment (after surgery)
Adjuvant treatment is given with the intent to kill any cancer cells left behind after surgery.
Overview
This image shows what happened three years after people started the study.
Details
Three years after people started the study:
At this time of this data review, it was too early in the study to determine if people lived longer with KADCYLA. However, people in the study will continue to be followed and evaluated.
This image shows that 1 infusion of KADCYLA is given every 3 weeks for 14 cycles.
This image shows that the first infusion of KADCYLA takes 90 minutes. If prior infusions were well tolerated, all other infusions take 30 minutes.
Your healthcare team will wait at least 90 minutes after the first infusion, and at least 30 minutes after each following infusion, to check for any reactions. If side effects occur, they may adjust, delay, or stop your treatment.
Wait 3 weeks between infusions.
This image shows a normal cell with a normal amount of HER2, in which cells grow and divide normally; and a HER2+ cancer cell with too much HER2, in which cells grow and divide faster.
This image shows that 1 infusion of KADCYLA is given every 3 weeks.
This image shows that the first infusion of KADCYLA takes 90 minutes. If prior infusions were well tolerated, all other infusions take 30 minutes.
Your healthcare team will wait at least 90 minutes after the first infusion, and at least 30 minutes after each following infusion, to check for any reactions. If side effects occur, they may adjust, delay, or stop your treatment.
Wait 3 weeks between infusions.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.